AP-2-Associated Protein Kinase 1 and Cyclin G-Associated Kinase Regulate Hepatitis C Virus Entry and Are Potential Drug Targets

Abstract

Hepatitis C virus (HCV) enters its target cell via clathrin-mediated endocytosis. AP-2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK) are host kinases that regulate clathrin adaptor protein (AP)-mediated trafficking in the endocytic and secretory pathways. We previously reported that AAK1 and GAK regulate HCV assembly by stimulating binding of the subunit of AP-2, AP2M1, to HCV core protein. We also discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HCV assembly. Here, we hypothesized that AAK1 and GAK regulate HCV entry independently of their effect on HCV assembly. Indeed, silencing AAK1 and GAK expression inhibited entry of pseudoparticles and cell culture grown-HCV and internalization of Dil-labeled HCV particles with no effect on HCV attachment or RNA replication. AAK1 or GAK depletion impaired epidermal growth factor (EGF)-mediated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib's cancer target. Moreover, either RNA interference-mediated depletion of AP2M1 or NUMB, each a substrate of AAK1 and/or GAK, or overexpression of either an AP2M1 or NUMB phosphorylation site mutant inhibited HCV entry. Last, in addition to affecting assembly, sunitinib and erlotinib inhibited HCV entry at a postbinding step, their combination was synergistic, and their antiviral effect was reversed by either AAK1 or GAK overexpression. Together, these results validate AAK1 and GAK as critical regulators of HCV entry that function in part by activating EGFR, AP2M1, and NUMB and as the molecular targets underlying the antiviral effect of sunitinib and erlotinib (in addition to EGFR), respectively. IMPORTANCEUnderstanding the host pathways hijacked by HCV is critical for developing host-centered anti-HCV approaches. Entry represents a potential target for antiviral strategies; however, no FDA-approved HCV entry inhibitors are currently available. We reported that two host kinases, AAK1 and GAK, regulate HCV assembly. Here, we provide evidence that AAK1 and GAK regulate HCV entry independently of their role in HCV assembly and define the mechanisms underlying AAK1-and GAK-mediated HCV entry. By regulating temporally distinct steps in the HCV life cycle, AAK1 and GAK represent "master regulators" of HCV infection and potential targets for antiviral strategies. Indeed, approved anticancer drugs that potently inhibit AAK1 or GAK inhibit HCV entry in addition to assembly. These results contribute to an understanding of the mechanisms of HCV entry and reveal attractive host targets for antiviral strategies as well as approved candidate inhibitors of these targets, with potential implications for other viruses that hijack clathrin-mediated pathways. H epatitis C virus (HCV) is a major global health problem, estimated to infect 170 million people worldwide (1, 2). HCV persistence results in severe liver disease, including cirrhosis, liver failure, and hepatocellular carcinoma (reviewed in reference...

Suppression of Nkx3.2 by phosphatidylinositol-3-kinase signaling regulates cartilage development by modulating chondrocyte hypertrophy

“…As shown in Fig. 3E, protein levels of Nkx3.2 in human primary chondrocytes were significantly augmented by administering IPA-3, a PAK1 inhibitor [58]. In addition, as seen in Fig.…”

Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase: synthesis, structure–activity relationship studies and antiviral activity

“…It has been shown that depletion of GAK by siRNA is dispensable for HCV RNA replication, but significantly inhibits two temporally distinct steps of the HCV life cycle: entry and assembly. 19,20 Similarly, pharmacological inhibitors of the kinase activity of GAK disrupted HCV entry and assembly, thereby further validating GAK as a potential antiviral target. Erlotinib (Figure 1), an approved anticancer drug that potently inhibits GAK as an off-target effect, effectively disrupted HCV entry and assembly.…”

“…Erlotinib (Figure 1), an approved anticancer drug that potently inhibits GAK as an off-target effect, effectively disrupted HCV entry and assembly. 19,20 Moreover, we recently reported the discovery of isothiazolo[4,3- b ]pyridines as a class of selective GAK inhibitors that are structurally unrelated to erlotinib. 21 The most potent compounds, 1 and 2, were endowed with Kd values of 8.3 and 8.9 nM, respectively (Figure 1).…”

Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection

“…Moreover, there was no difference between the wild-type virus and the W420 mutants. The main target of erlotinib is EGFR; however, Neveu et al recently reported that erlotinib also inhibits cyclin G-associated kinase (GAK) during HCV entry (63). GAK is a regulator of clathrin-mediated endocytosis that recruits clathrin and AP-2 to the plasma membrane.…”

“…The host cell kinase AP-2-associated protein kinase 1 (AAK1) is a second regulator of AP-2 clathrinmediated endocytosis. AAK1 was also shown to regulate EGFRmediated HCV entry (63). Therefore, we used sunitinib, a kinase inhibitor that targets AAK1, to investigate if the W420 mutants require AAK1.…”